India’s GLP-1 surge: domestic drugmakers challenge Novo and Lilly

India’s GLP-1 drug market is poised for explosive growth, outpacing global trends and positioning domestic pharma giants to challenge multinational dominance.

Though global players like Novo Nordisk (NOV: N) and Eli Lilly (NYSE: LLY) dominate the branded GLP-1 space, Indian pharma is rapidly gaining ground, both domestically and in export markets, with a potential $20 billion opportunity on the horizon, reports The Pharma Letter’s India correspondent.

Home to over 100 million obese adults and often dubbed the diabetes capital of the world, India is emerging as a pivotal force in the global metabolic health revolution. With GLP-1 drugs projected to reach $150 billion globally by 2030, Indian pharma companies are preparing to enter with generics and biosimilars.